Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoglitazone Monotherapy in Type 2 Diabetes
NCT00571519Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2007
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rivoglitazone in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Glycosylated Hemoglobin (A1c) at 20 weeks. Started Nov 2007; status: terminated.
02
Drugs
rivoglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00571519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571519.